Realizing Chemotherapy as a Therapeutic Option for Prostate Cancer

Dr. Thomas Buckley (2002 Research Grant)

Although, chemotherapy is a popular cancer therapy, it is not as effective for prostate cancer. Chemotherapy is also harmful to healthy cells. As a result, it is not a popular treatment for prostate cancer. In 2002 we granted Dr. Thomas Buckley funds to research a prostate cancer-specific toxin. His work has been very successful; he has developed a drug called PRX302 which selectively and effectively kills PSA-producing cells without harming other tissues.

The results of the initial study were so encouraging that a company, called Protox Therapeutics, was formed to further develop the idea and hopefully bring the discovery to market. The drug is now in phase II clinical trails.

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More


Click here for news archive